Skip to content

Randomized Study of the Safety and Effectiveness of the TearCare System for the Signs and Symptoms of Dry Eye Disease

Randomized, Controlled Trial to Evaluate the Safety and Effectiveness of the TearCare® System in the Treatment of the Signs and Symptoms of Dry Eye Disease

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03502447
Enrollment
14
Registered
2018-04-18
Start date
2018-04-20
Completion date
2018-12-04
Last updated
2025-09-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry Eye Syndromes

Brief summary

In this study, the TearCare System will be compared with standard-of-care warm compress treatment and lid massage in patients with dry eye disease. The objective is to demonstrate that the TearCare System is safe and effective in relieving the signs and symptoms of dry eye disease and that it is superior to a commonly prescribed, standard treatment of warm compress and lid massage. NOTE: All sites have been selected for this study.

Detailed description

This prospective, randomized, controlled, single-masked, multi-center treatment study will recruit 200 subjects with dry eye disease (OSDI Score of ≥23, TBUT of ≤7 seconds in both eyes, Meibomian gland obstruction in both eyes based on a total Meibomian Gland Secretion Score ≤12 in each eye and best corrected visual acuity of 20/100 or better in both eyes). Subject will be at least 22 years of age with reports of dry eye symptoms within the past 3 months, having to use artificial tears or lubricants regularly over the past month to relieve dry eye symptoms and willingness to comply with the study procedures and follow-up for 12 months. All subjects will complete an informed consent form indicating their voluntary participation in the study. Study Measurements will be made at baseline (Day 0 - randomization to TearCare or Warm Compress/Lid Massage) and at Day 1, Week 1, and Months 1, 3, 6, 7, 9, 12.

Interventions

DEVICETearCare

TearCare treatment includes an in-office 15 minute thermal treatment session where heat is delivered to the eyelids. This is immediately followed by manual clearing of the meibomian glands.

DEVICEWarm Compress and Lid Massage

Subjects randomized to the Warm Compress and Lid Massage Group will be instructed to apply a moist, warm compress to their eyelids daily for 5 minutes and then perform lid massage.

Sponsors

Sight Sciences, Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
22 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Diagnosed with dry eye disease * Signs and symptoms of dry eye disease * Best corrected visual acuity 20/100 or better * Willing and able to comply with study procedures * Willing and able to provide consent

Exclusion criteria

* Active ocular infection or inflammation * History of eyelid, conjunctiva or corneal surgery within the past year. * Recent office-based dry eye treatment, punctal occlusion or punctal plug placement * Contact lens wearer * Significant ocular surface or eyelid abnormalities, recent ocular trauma * Certain corneal surface abnormalities * Use of medications for treatment of dry eye or medications that cause dry eye * Systemic disease that results in dry eye

Design outcomes

Primary

MeasureTime frameDescription
Mean Change in Tear Break-Up Time From Baseline to Month 11 monthThe TBUT was evaluated by measuring the time to breakup of the tear film following a complete blink when viewed through the slit-lamp using a cobalt blue filter. The TBUT was recorded using a stopwatch for each eye as the average of 3 measurements at each visit. The change in TBUT was The difference between the mean baseline value and the mean Month 1 value. The TBUT for each eye for a subject was averaged. The mean change in TBUT is the Month 1 value minus the baseline value for each subject which are then averaged. An increase in TBUT is an improvement.

Secondary

MeasureTime frameDescription
Mean Change in OSDI Score From Baseline to Month 11 monthThe Ocular Surface Disease Index (OSDI) is a 12-item questionnaire that assesses symptoms of ocular irritation associated with dry eye and the impact of these on vision-related activities. The OSDI score ranges from 0 (best possible) to 100 (worst possible). The change in OSDI questionnaire from baseline to Month 1 is the difference between the scores at the two timepoints. A negative value would indicate improvement and a positive value, a worsening. The reported value is the mean of the change for all subjects.

Countries

United States

Participant flow

Participants by arm

ArmCount
TearCare
TearCare subjects will receive TearCare thermal treatment followed by manual clearing of the meibomian glands. TearCare: TearCare treatment includes an in-office 15 minute thermal treatment session where heat is delivered to the eyelids. This is immediately followed by manual clearing of the meibomian glands.
7
Warm Compress & Lid Massage
Subjects will perform warm compress and lid massage at home daily. Warm Compress and Lid Massage: Subjects randomized to the Warm Compress and Lid Massage Group will be instructed to apply a moist, warm compress to their eyelids daily for 5 minutes and then perform lid massage.
7
Total14

Baseline characteristics

CharacteristicTearCareWarm Compress & Lid MassageTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
6 Participants4 Participants10 Participants
Age, Categorical
Between 18 and 65 years
1 Participants3 Participants4 Participants
Age, Continuous69 years
STANDARD_DEVIATION 10.1
55.9 years
STANDARD_DEVIATION 20.9
62.45 years
STANDARD_DEVIATION 18.4
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
2 Participants1 Participants3 Participants
Race (NIH/OMB)
Black or African American
0 Participants0 Participants0 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
5 Participants6 Participants11 Participants
Region of Enrollment
United States
7 Participants7 Participants14 Participants
Sex: Female, Male
Female
3 Participants3 Participants6 Participants
Sex: Female, Male
Male
4 Participants4 Participants8 Participants
Tear Break Up Time4.9 seconds
STANDARD_DEVIATION 0.8
4.7 seconds
STANDARD_DEVIATION 0.7
4.8 seconds
STANDARD_DEVIATION 0.8

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 70 / 7
other
Total, other adverse events
0 / 70 / 7
serious
Total, serious adverse events
0 / 70 / 7

Outcome results

Primary

Mean Change in Tear Break-Up Time From Baseline to Month 1

The TBUT was evaluated by measuring the time to breakup of the tear film following a complete blink when viewed through the slit-lamp using a cobalt blue filter. The TBUT was recorded using a stopwatch for each eye as the average of 3 measurements at each visit. The change in TBUT was The difference between the mean baseline value and the mean Month 1 value. The TBUT for each eye for a subject was averaged. The mean change in TBUT is the Month 1 value minus the baseline value for each subject which are then averaged. An increase in TBUT is an improvement.

Time frame: 1 month

ArmMeasureValue (MEAN)Dispersion
TearCareMean Change in Tear Break-Up Time From Baseline to Month 11.4 secondsStandard Deviation 2.3
Warm Compress & Lid MassageMean Change in Tear Break-Up Time From Baseline to Month 12.5 secondsStandard Deviation 2.8
Secondary

Mean Change in OSDI Score From Baseline to Month 1

The Ocular Surface Disease Index (OSDI) is a 12-item questionnaire that assesses symptoms of ocular irritation associated with dry eye and the impact of these on vision-related activities. The OSDI score ranges from 0 (best possible) to 100 (worst possible). The change in OSDI questionnaire from baseline to Month 1 is the difference between the scores at the two timepoints. A negative value would indicate improvement and a positive value, a worsening. The reported value is the mean of the change for all subjects.

Time frame: 1 month

ArmMeasureValue (MEAN)Dispersion
TearCareMean Change in OSDI Score From Baseline to Month 1-13.7 units on a scaleStandard Deviation 12.5
Warm Compress & Lid MassageMean Change in OSDI Score From Baseline to Month 1-10.0 units on a scaleStandard Deviation 7.7

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026